Payment overview · 2025
General Payments
$156.51
10 reported records · 5 companies
Healthcare provider profile · identity verified
David L Mcclain, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RUSSELLVILLE, KY · NPI 1790771954
Verified facts
What the public records show
CMS Open Payments records show David L Mcclain, ARNP received $156.51 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.82 | 32.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.59 | 29.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.26 | 18.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.62 | 10.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.22 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $156.51 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.26 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.26 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 682 | 92 |
| Gabapentin | Gabapentin | 618 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 544 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 102 |
| Lisinopril | Lisinopril | 470 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 81 |
| Losartan Potassium | Losartan Potassium | 345 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 78 |
| Montelukast Sodium | Montelukast Sodium | 328 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 61 |
| Omeprazole | Omeprazole | 309 | 74 |
| Metformin Hcl | Metformin Hcl | 306 | 53 |
| Azithromycin | Azithromycin | 286 | 167 |
| Furosemide | Furosemide | 286 | 80 |
| Alprazolam | Alprazolam | 282 | 34 |
| Potassium Chloride | Potassium Chloride | 263 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 97 |
| Levofloxacin | Levofloxacin | 250 | 138 |
| Methylprednisolone | Methylprednisolone | 243 | 138 |
| Trazodone Hcl | Trazodone Hcl | 238 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 40 |
| Tramadol Hcl | Tramadol Hcl | 189 | 39 |
| Ondansetron Odt | Ondansetron | 180 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 38 |
| Eliquis | Apixaban | 167 | 29 |
| Prednisone | Prednisone | 166 | 86 |
| Carvedilol | Carvedilol | 158 | 35 |
| Meloxicam | Meloxicam | 157 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 33 |
| Sertraline Hcl | Sertraline Hcl | 143 | 37 |
| Clonazepam | Clonazepam | 141 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 58 |
| Ropinirole Hcl | Ropinirole Hcl | 136 | 32 |
| Buspirone Hcl | Buspirone Hcl | 135 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 28 |
| Famotidine | Famotidine | 117 | 28 |
| Simvastatin | Simvastatin | 113 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 23 |
| Cefdinir | Cefdinir | 110 | 71 |
| Farxiga | Dapagliflozin Propanediol | 110 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 103 | 79 |
| Promethazine Hcl | Promethazine Hcl | 103 | 22 |
| Metformin Hcl Er | Metformin Hcl | 98 | 24 |
| Celecoxib | Celecoxib | 97 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 16 |
| Ibuprofen | Ibuprofen | 96 | 35 |
| Ozempic | Semaglutide | 96 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Allopurinol | Allopurinol | 87 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 14 |
| Glipizide Er | Glipizide | 85 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 13 |
| Aripiprazole | Aripiprazole | 82 | 14 |
| Fenofibrate | Fenofibrate | 81 | 16 |
| Nifedipine Er | Nifedipine | 79 | 14 |
| Xarelto | Rivaroxaban | 77 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 76 | 13 |
| Pregabalin | Pregabalin | 76 | 11 |
| Fluconazole | Fluconazole | 75 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 70 | 43 |
| Estradiol | Estradiol | 67 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 18 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 24 |
| Glipizide | Glipizide | 55 | suppressed |
| Jardiance | Empagliflozin | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 22 |
| Spironolactone | Spironolactone | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 31 |
| Baclofen | Baclofen | 45 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 22 |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 21 |
| Nitroglycerin | Nitroglycerin | 40 | 16 |
| Sucralfate | Sucralfate | 40 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Methocarbamol | Methocarbamol | 39 | 12 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Linzess | Linaclotide | 37 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 34 |
| Temazepam | Temazepam | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 36 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 18 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Loperamide | Loperamide Hcl | 34 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Metronidazole | Metronidazole | 31 | 23 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 21 |
| Cephalexin | Cephalexin | 29 | 24 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 15 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $156.51 · 10 records | Amgen Inc. | Auvelity, BREZTRI, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error